Steve Hahn, Flagship CEO-Partner and CEO of Harbinger Health, explains how the company is pioneering the detection of early cancer through blood-based tests, what’s ahead for their multi-tier testing program, and what this means for expanding access to cancer screening. More from Flagship @ JPM2024 here.
More from:
Human Health
What If We Could See Disease Coming and Stop It?
Amanda Kay on a New Approach to Biopharma Partnerships
Pioneering Partnerships: Advancing a Portfolio of Novel Medicines and Vaccines with GSK
Pioneering Partnerships: Accelerating our Collaboration with Pfizer
Unlocking Therapeutic Breakthroughs with the Power of Platform Technologies
